|
Summary
January 2006, Vol. 7, No. 1, Pages 49-59
, DOI 10.2217/14622416.7.1.49
(doi:10.2217/14622416.7.1.49)
Research Report Patients’ and physicians’ perspectives on pharmacogenetic testing Anja Rogausch 1†, Daniela Prause 1, Anne Schallenberg 1, Jürgen Brockmöller 2 & Wolfgang Himmel 11Georg-August-University Göttingen, Department of General Practice/Family Medicine, Humboldtallee 3837073 Göttingen, Germany. arogaus@gwdg.de 2Georg-August-University Göttingen, Department of Clinical Pharmacology, Germany † Author for correspondence Introduction: The integration of pharmacogenetic testing into routine care will, in part, depend upon the patients’ and physicians’ acceptance of these tests. Empirical data regarding patients’ and physicians’ views on pharmacogenetic testing are lacking. Objectives: To explore patients’ and physicians’ perspectives on the potential implications of pharmacogenetic testing, particularly focusing on asthma, and to analyze the possible determinants of their expectations, hopes and fears. Methods: We conducted telephone interviews with patients with asthma or chronic obstructive pulmonary disease taking part in a larger pharmacogenetic study, in addition to general practitioners (GPs) from a different region in Germany. A total of 328 patients and 378 GPs were invited to participate. Determinants of their attitudes toward pharmacogenetic testing were assessed using logistic regression analysis. Results: Informed consent to participate in this study was given by 196 patients (60%) and 106 GPs (28%). Most patients (96%) and physicians (52%) appreciated the availability of pharmacogenetic tests for a disease such as asthma. Approximately a third of the patients worried about potential unfavorable test results (35%) and violation of privacy (36%). Female patients were more likely to have a fearful attitude (odds ratio [OR] = 2.85; 95% confidence interval [CI] = 1.58–5.12). Younger patients were generally more likely to be hopeful about the usefulness of pharmacogenetic testing (OR = 2.12; CI = 1.01–4.46). The GPs’ concerns were mainly related to the possibility that patients might either be put under pressure to be tested (72%) or be disadvantaged at private health insurance agencies (61%). The nature of the responsible institution, the clarity of the research aim and explicit informed consent from patients influenced a physicians’ decision regarding whether to support a pharmacogenetic study. Conclusion: The concerns of patients and GPs differ somewhat with respect to negative psychosocial consequences, discrimination or violation of privacy. Development of information for physicians and patients would be helpful in preventing unrealistic fears or hopes.
Cited byDonna K Arnett, Steven A Claas, Amy I Lynch. (2009) Has pharmacogenetics brought us closer to ‘personalized medicine’ for initial drug treatment of hypertension?. Current Opinion in Cardiology 24:4, 333-339 Online publication date: 1-Aug-2009. CrossRef Michael Barr, Diana Rose. (2008) The great ambivalence: factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. Sociology of Health & Illness 30:6, 944-958 Online publication date: 1-Oct-2008. CrossRef Peter Finegold, Kate Mathieson, Leah Holmes, Martin Boon, Mark Cottle, Dian Donnai, Helen Middleton-Price. (2008) Is the UK public ready for genetic medicine?. Personalized Medicine 5:1, 65-76 Online publication date: 1-Jan-2008. Summary
| Full Text
| PDF (413 KB)
| PDF Plus (338 KB) Emily A Fargher, Charlotte Eddy, William Newman, Faieza Qasim, Karen Tricker, Rachel A Elliott, Katherine Payne. (2007) Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8:11, 1511-1519 Online publication date: 1-Nov-2007. Summary
| Full Text
| PDF (200 KB)
| PDF Plus (213 KB) Nathalie Égalité, Vural Özdemir, Béatrice Godard. (2007) Pharmacogenomics research involving racial classification: qualitative research findings on researchers’ views, perceptions and attitudes towards socioethical responsibilities. Pharmacogenomics 8:9, 1115-1126 Online publication date: 1-Sep-2007. Summary
| Full Text
| PDF (258 KB)
| PDF Plus (259 KB)
|
|
|